Enzo Biochem Inc. (NYSE:ENZ) Q4 2020 Earnings Conference Call - Final Transcript
Oct 13, 2020 • 04:30 pm ET
Greetings and welcome to the Enzo Biochem, Inc. Fourth Quarter and Fiscal 2020 Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Jeremy Feffer, Investor Relations for Enzo Biochem, Inc. Thank you. You may begin.
Thank you, Doug and good afternoon. Joining us today from the Company are Barry Weiner, Co-Founder and President; and David Bench, Chief Financial Officer.
A press release announcing the results and the update was issued this afternoon and is available now on the Enzo website. I will now read the Company's Safe Harbor statement. Except for historical information, the matters discussed in this news release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues and expenses, which are dependent on a number of factors outside of the control of the Company, including the markets for the Company's products and services, cost of goods and services, other expenses, government regulations, litigation and general business conditions. Please see Risk Factors in the Company's Form 10-K for the fiscal year ended July 31st, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results.
The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this conference call. During this conference call, the Company may refer to EBITDA, a non-GAAP measure. EBITDA is not and should not be considered an alternative to net income-loss, income loss from operations or any other measure for determining operating performance. The Company has provided a reconciliation of the difference to GAAP on its website www.enzo.com and in its press release issued this afternoon.
I would now like to turn -- I would now like to turn the floor over to Barry Weiner, Co-founder and President of Enzo Biochem. Barry, please go ahead.
Barry W. Weiner
Thank you, Jeremy. Good afternoon and thank you for joining us on our quarterly update call today. We issued our fourth quarter and fiscal year 2020 financial and operating results after the close of the market tonight, hope you had a chance to look at them. This period has presented unprecedented issues for our country, business community, and Enzo specifically, as a first-line responder in providing approaches for testing that address the needs of our population.
We completed the fourth quarter making significant achievements in the three core objectives which we defined in the past. Despite unprecedented conditions due to COVID-19 and the Company's mobilization to address the needs of the market. These objectives were: first, transforming from a bifurcated life sciences company to an integrated end-to-end diagnostics company; second, was building the infrastructure